Redx Pharma, a drug discovery and development company, has sealed a long-term funding deal that will see it list on the US-based Nasdaq exchange as Fibrx Therapeutics. Based in Macclesfield, Redx is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease. The news follows … Continue reading $125m financing to see Macclesfield’s Redx list on Nasdaq